Rating agency CRISIL Research has revised Panacea Biotec’s CRISIL IER fundamental grade to ‘2/5’ from ‘3/5’. The grade indicates that the company’s fundamentals are ‘moderate’ relative to other listed equity securities in India. Further, the rating agency has assigned a valuation grade of ‘3/5’ to the company.
The fundamental grade has been revised downwards after factoring in Panacea’s weak business footing following the recent delisting of oral polio vaccine (OPV) by World Health Organisation (WHO).
Panacea Biotec is one of India’s leading research based health management companies with established research, manufacturing and marketing capabilities.
